NCT06637306 is a EARLY_PHASE1 clinical trial of Dupilumab in Locally Advanced Triple Negative Breast Cancer, sponsored by Rima Patel.

Who is sponsoring NCT06637306?

NCT06637306 is sponsored by Rima Patel.

What drugs are being tested in NCT06637306?

Interventions in NCT06637306: Dupilumab, Pembrolizumab, Paclitaxel, Carboplatin.

What condition does NCT06637306 study?

NCT06637306 studies Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer.

Is NCT06637306 still recruiting?

NCT06637306 is currently recruiting now. Last updated 26 March 2025.

Last reviewed 2025-03-26 · How we verify

NCT06637306

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Recruiting now EARLY_PHASE1 Last updated 26 March 2025

What this trial tests

EARLY_PHASE1 trial testing Dupilumab in Locally Advanced Triple Negative Breast Cancer in 15 participants. Currently enrolling.

Timeline

5 March 2025

Primary endpoint
31 December 2026

1 June 2027

Quick facts

Lead sponsor	Rima Patel
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	5 March 2025
Primary completion	31 December 2026
Estimated completion	1 June 2027
Sites	1 location across United States

Drugs / interventions tested

Dupilumab (DUPILUMAB) — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →
Paclitaxel — full drug profile →
Carboplatin (Carboplatin) — full drug profile →

Conditions studied

Locally Advanced Triple Negative Breast Cancer — all drugs for Locally Advanced Triple Negative Breast Cancer →
TNBC - Triple-Negative Breast Cancer — all drugs for TNBC - Triple-Negative Breast Cancer →

Sponsor

Rima Patel

Who can join

18 and older, any sex, with Locally Advanced Triple Negative Breast Cancer or TNBC - Triple-Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pilot trial of the IL-4 receptor antagonist dupilumab plus pembrolizumab, paclitaxel, and carboplatin in locally advanced triple negative breast cancer (TNBC). Primary Objective: To assess the safety of neoadjuvant dupilumab and pembrolizumab plus weekly paclitaxel and carboplatin as measured by the proportion of severe immune-related adverse events (irAEs) in patients with locally advanced TNBC. Secondary Objectives: To determine the rates of pathologic complete response with the addition of dupilumab to NAC and pembrolizumab; to determine the rate of residual cancer burden 0-1; to estimate the recurrence-free survival and overall survival; to assess the toxicity of the combination of dupilumab, pembrolizumab, and paclitaxel-carboplatin.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor secretome shapes the immune landscape during cancer progression.
Yang J, Tang S, Saba NF, Shay C, et al · · 2025 · cited 16× · PMID 39930476 · DOI 10.1186/s13046-025-03302-0
Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer.
Corti C, Koca B, Rahman T, Mittendorf EA, et al · · 2025 · cited 11× · PMID 40196378 · DOI 10.2147/itt.s495751
Steroid-sparing strategies for managing immune-related adverse events.
Huang JJ, YousefiAsl M, Singh N, Grivas P, et al · · 2026 · cited 1× · PMID 41545303 · DOI 10.1136/jitc-2025-013776
Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis.
Mukherjee S, Ghosh A, Chakraborty S, Basak U, et al · · 2025 · PMID 41019045 · DOI 10.3389/fimmu.2025.1655176

Verify or expand the search:

Other trials of Dupilumab

Trials testing the same drug.

NCT07316114 — A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spont · recruiting
NCT07277322 — Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases · Phase 1, PHASE2 · not yet recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07399067 — A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06637306 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rima Patel
Last refreshed: 26 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06637306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing